Moderna Inc (NASDAQ:MRNA) shares are trading higher Wednesday after the company announced that MRNA-1283 met the primary endpoints in its Phase 3 clinical trial. Additionally, Blackstone Life Sciences announced an investment to support the company’s influenza program. What Happened: Moderna held its fifth Vaccines Day event this week and announced clinical and program updates demonstrating advancement and acceleration of its mRNA pipeline. The company said multiple vaccine programs have advanced to late-stage clinical trials. Moderna on Tuesday announced that its next-generation COVID-19 vacci…